Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.

Methods Mol Biol

Division of Cancer Medicine, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dendritic cell (DC) cancer vaccines have become an established treatment modality for patients with a wide range of cancers. However, the therapeutic potential of this immunotherapy is often limited by negative feedback mechanisms that normally prevent sustained activation of the immune system, thereby reducing the risk of autoimmunity. To overcome these challenges, a new generation of DC vaccines have been developed using RNA interference (RNAi) technology to inhibit the expression of immunosuppressive factors, such as indoleamine 2,3-dioxygenase 1 (IDO1). The developed vaccines effectively stimulated T cells and demonstrated anti-tumor activity in cancer patients. This chapter describes the design and enzymatic synthesis of siRNA targeting IDO, along with its incorporation into DC vaccines under Good Manufacturing Practice.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-0716-4742-4_12DOI Listing

Publication Analysis

Top Keywords

enhancing cancer
4
cancer vaccine
4
vaccine efficacy
4
efficacy sirna-based
4
sirna-based modulation
4
modulation immune
4
immune suppressive
4
suppressive factors
4
factors dendritic
4
dendritic cells
4

Similar Publications

Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.

View Article and Find Full Text PDF

Importance: Increasingly, strategies to systematically detect melanomas invoke targeted approaches, whereby those at highest risk are prioritized for skin screening. Many tools exist to predict future melanoma risk, but most have limited accuracy and are potentially biased.

Objectives: To develop an improved melanoma risk prediction tool for invasive melanoma.

View Article and Find Full Text PDF

Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.

View Article and Find Full Text PDF

Objective: This study aims to systematically evaluate the inter- and intra-observer agreement regarding lesions with uncertain malignancy potential in Ga-68 PSMA PET/CT imaging of prostate cancer patients, utilizing the PSMA-RADS 2.0 classification system, and to emphasize the malignancy evidence associated with these lesions.

Methods: We retrospectively reviewed Ga-68 PSMA PET/CT images of patients diagnosed with prostate cancer via histopathology between December 2016 and November 2023.

View Article and Find Full Text PDF

Deciphering the molecular landscape of acute myeloid leukemia initiation and relapse: a systems biology approach.

Med Oncol

September 2025

Division of Hematology and Blood Bank, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Acute Myeloid Leukemia (AML) patient-derived Mesenchymal Stem Cells (MSCs) behave differently than normal ones, creating a more protective environment for leukemia cells, making relapse harder to prevent. This study aimed to identify prognostic biomarkers and elucidate relevant biological pathways in AML by leveraging microarray data and advanced bioinformatics techniques. We retrieved the GSE122917 dataset from the NCBI Gene Expression Omnibus and performed differential expression analysis (DEA) within R Studio to identify differentially expressed genes (DEGs) among healthy donors, newly diagnosed AML patients, and relapsed AML patients.

View Article and Find Full Text PDF